DURECT (NASDAQ:DRRX) was up 4% premarket on light volume, potentially adding to its 88% rally since December 16. Investors appear to be expecting good news from the FDA’s review of the company’s responses to the CRL it received in February 2014 related to its marketing application for pain med Posimir (bupivacaine) citing the need for more safety data.
The agency’s action date was December 27.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.